Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has received a consensus rating of “Moderate Buy” from the nineteen research firms that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and one has issued a strong buy recommendation […]
More Stories
Otter Tail (NASDAQ:OTTR) Announces Quarterly Earnings Results
Otter Tail (NASDAQ:OTTR – Get Free Report) issued its quarterly earnings results on Monday. The utilities provider reported $2.03 earnings...
SEA (SE) Scheduled to Post Quarterly Earnings on Tuesday
SEA (NYSE:SE – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on...
Ashland (ASH) to Release Earnings on Wednesday
Ashland (NYSE:ASH – Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on...
Premia 24-Hour Volume Tops $4,858.50 (PREMIA)
Premia (PREMIA) traded 0.3% lower against the dollar during the 1-day period ending at 13:00 PM Eastern on November 5th....
Fiduciary Family Office LLC Sells 214 Shares of American Express (NYSE:AXP)
Fiduciary Family Office LLC reduced its stake in shares of American Express (NYSE:AXP) by 2.5% during the third quarter, according...
PDS Planning Inc Acquires 34 Shares of Northrop Grumman Co. (NYSE:NOC)
PDS Planning Inc increased its holdings in shares of Northrop Grumman Co. (NYSE:NOC – Free Report) by 5.4% in the...